Both KRAS or PTEN mutated models showed background neoplastic lesions (lymphoma) (KRAS: n = 7 vs. PTEN: n = 3; Figure 4C) and undifferentiated tumors (KRAS: n = 4 vs. PTEN: n = 1 Figure 4C) with a slight predominance of the KRAS models in both categories. This evidence concerns the gene KRAS and lymphoma.